A viral strategy to ambush tumors

A new combinatorial approach harnesses the power of immuno- and virotherapy in a vesicular stomatitis virus (VSV) vector carrying a cDNA library that expresses normal human prostate antigens, thus providing proof of principle that this vaccine can induce prostate tumor rejection in mice (pages 854-859). This strategy might bypass many of the issues associated with conventional cancer immuno- or virotherapy.